Navigation Links
Biozoom Exercises Purchase Option Under Joint Venture Agreement With Spectroscopic Technology Developer, Opsolution
Date:6/14/2013

AGOURA HILLS, Calif., June 14, 2013 /PRNewswire/ -- Biozoom (OTC QB: BIZM) exercised its option, under a joint venture agreement, to acquire 19.9% of Opsolution, a research and development company dedicated to advancing spectroscopic technology.  Pursuant to the joint venture between the two companies, Opsolution assigned to Biozoom all of its rights to Opsolution's future intellectual property, whether developed or acquired, including licenses and royalty rights. In exchange, Biozoom agreed to fund Opsolution's ongoing research and development activities by matching certain grant funds awarded to Opsolution by the German government.  Under Biozoom's asset purchase agreement with Opsolution, executed in parallel with the joint venture, Biozoom acquired all of Opsolution's existing tangible and non-tangible assets.

"Both companies can concentrate on what they do best," said Hardy Hoheisel, CEO of Biozoom. "Opsolution can focus on the R & D, while Biozoom aggressively pursues large-scale sales opportunities and relationships with distribution partners in the health and wellness industry."

The joint venture agreement gives Biozoom access to intellectual property and patents as they are developed and acquired. "Opsolution is conducting the research that we hope will enable our next generation Biozoom scanner to measure common medical values, including cholesterol and blood sugar levels. We believe this will lead to wide adoption by the healthcare community when the new scanner is perfected," said Hoheisel.

Opsolution developed the ground-breaking technology to miniaturize laboratory-quality spectroscopy, enabling the creation of Biozoom's mobile handheld device. This miniaturization was based on collaboration with one of the world's leading optical engineering companies, Carl Zeiss. This optics technology is at the heart of the current scanner, the world's first portable, handheld device for the non-invasive transdermal analysis of biomarkers—including antioxidant levels. The Biozoom scanner's accuracy has been validated by one of Europe largest teaching hospitals, where it is in regular clinical use.

Opsolution's work toward further reducing the size of the optical scanner to nanoscopic scale has led to significant research and development grant interest from the German government.

About Biozoom

Biozoom is an innovative technology development company, specializing in the commercialization of our advances in mobile spectroscopy.  Our intellectual property portfolio and ongoing research are positioned to apply Biozoom's technology breakthroughs to a wide range of markets. Our first consumer product, the Biozoom scanner, gives people the feedback they need to manage their health, wellness and fitness on demand.  Tested in leading health institutions, our scanner is the first of its kind—a handheld, transdermal device for measuring biomarkers, including antioxidant levels, at the click of a button. Scan results— and customized wellness coaching based on those biomarkers— are sent instantly to a smartphone or online account.  The scanner will enable leaders in the health and wellness industry to create new levels of customer loyalty and revenues as a result. For more information, visit www.biozoom.net.

Disclaimer

This press release contains "forward-looking statements". Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future, and specifically references to future potential purchase orders and re-orders from consumers and distributors. The reader can identify these forward-looking statements by forward-looking words such as "may," "will," "expect," "potential," "anticipate," "forecast," "believe," "estimate," "project," "plan," "continue" or similar words. The reader should read statements that contain these words carefully because they discuss future expectations, contain projections of future results of operations or of financial condition, or state other forward-looking information. Forward-looking statements include, but are not limited to, statements regarding potential products, customers, revenues, expansion efforts, and future plans and objectives of Biozoom, Inc. ("Biozoom"). The risk factors listed in our disclosure documents and the cautionary language therein provide examples of risks, uncertainties and events that may cause actual results to differ materially from the expectations and projections described by Biozoom in its forward-looking statements. Actual results relating to, among other things, product launch, sales, customer acceptance and market share could differ materially from those currently anticipated in such statements. Factors affecting forward-looking statements include: consumer preferences, competition from more established brands, ability to develop market share; changes in the operating costs; changes in economic conditions, foreign exchange and other financial markets; changes of the interest rates on borrowings; changes in the investments levels; litigation; legislation; environmental, judicial, regulatory, political and competitive developments in areas in which Biozoom operates; technological, mechanical and operational difficulties encountered in connection with Biozoom's development activities; and labor relation matters and costs. The reader should refer to the risk disclosures set out in the periodic reports and other disclosure documents filed by Biozoom from time to time with the Securities and Exchange Commission and other regulatory authorities.


'/>"/>
SOURCE Biozoom
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Biozoom Launches Sales & Business Development Office In Strategic Southern California Location
2. Biomedical Advanced Research and Development Authority (BARDA) Exercises Option with Pfenex Inc. To Extend Contract for the Development of a Recombinant Protective Antigen (rPA) Based Anthrax Vaccine
3. Array BioPharma Announces Exercise Of Underwriters Option To Purchase An Additional $17.25 Million Of 3.00% Convertible Senior Notes
4. Isis Pharmaceuticals Announces Exercise of Underwriters Option to Purchase Additional Shares
5. Vasomedical Announces Share Repurchase Program of up to $1.5 Million in Common Stock
6. Precision Optics Corporation Announces Reciept Of $660,000 Purchase Order For Custom-Designed Endoscopes
7. PAREXEL International Provides Update On Share Repurchase Program, Announces A New $50 Million Accelerated Share Repurchase Agreement And A New $50 Million 10b5-1 Trading Plan
8. WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2012 Results, Share Repurchase Program
9. Roswell Park Cancer Institute Purchases Six Ion Torrent Sequencers
10. BioMed Realty Trust Announces Exercise Of Option To Purchase Additional Shares Of Common Stock
11. xG Technology Receives $2,500,000 Purchase Commitment for xMax Broadband Network Equipment from Telemedicine-MM Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... PUNE, India , May 27, 2016 ... in the instances of hypertension is driving ambulatory blood ... muscles lose their elasticity and their ability to respond ... blood pressure. This condition can lead to various cardiovascular ... and peripheral vascular disease. These diseases are growing in ...
(Date:5/26/2016)... , May 26, 2016 According ... "Medical Waste Management Market - U.S. Industry Analysis, Size, Share, ... management market in the U.S. was valued at US$ 5.89 ... CAGR of 3.4% from 2015 to 2023 to reach US$ ... analysis of current and emerging needle free drug delivery devices ...
(Date:5/25/2016)... May 25,2016 FDA 510(k) ... Cellvizio platform for urological and surgical applications ... inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy ... in the US with the 12 th ... Administration (FDA). This new FDA clearance covers Confocal ...
Breaking Medicine Technology:
(Date:5/28/2016)... ... 2016 , ... After a year and a half of planning the Multiple Pathways of ... Multiple Pathways of Recovery Conference was held May 2 -4, 2016 at the Mystic ... came together to explore the many pathways individuals use to get into and sustain their ...
(Date:5/27/2016)... ... May 27, 2016 , ... Two director-level employees of Horizon Blue Cross Blue ... Industry (TWIN) 2016 honorees. The award recognizes businesswomen who excel in their fields ... Director of the MLTSS (Managed Long-Term Services and Supports) Program at Horizon NJ Health ...
(Date:5/27/2016)... ... , ... This campaign aims to provide a path to improved education and ... and change. , As nearly 795,000 Americans suffering from a new or recurrent stoke ... with an estimated 129,000 of these people dying from stroke, it’s become our nation’s ...
(Date:5/27/2016)... ... 27, 2016 , ... Aimed at nurses and employees in ... courtesy of leaders in the nursing and health care industry. It also provides ... and associations—namely Jones & Bartlett Learning. , Jones & Bartlett Learning is adding ...
(Date:5/26/2016)... ... ... Despite last week’s media reports hinting at a June rate hike after the ... for an interest rate increase, according to Rajeev Dhawan of the Economic Forecasting Center ... Market Committee (FOMC) dot charts are of interest to the press for their noise ...
Breaking Medicine News(10 mins):